Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision

Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The new Daxor BVA^™ device quantifies a patient’s blood volume against patient-specific norms, enabling precise fluid management across a broad spectrum of clinical conditions affecting millions of patients each year.

Read more at globenewswire.com